 |
|
|
| |
High Prevalence of Previously Undocumented Baseline M184V/I Does Not Affect Virologic Outcome in Virologically-Suppressed Patients Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from a Boosted Protease Inhibitor-based Regimen
|
| |
| |
Reported by Jules Levin
HIV Glasgow, 28-31 October 2018, Glasgow, UK
Kristen Andreatta, Richard Haubrich, Madeleine Willkom, Ross Martin, Silvia Chang, Rima Acosta, Ya-Pei Liu, Hiba Graham, Erin Quirk, and Kirsten L. White
Gilead Sciences, Inc., Foster City, CA 94404 USA
|
| |
|
|
|
|
|
